during a routine monitoring visit, the monitor discovers the investigator failed to report to both sponsor and irb an unanticipated adverse event of a subject who developed a severe rash immediately after taking the investigational drug. the subject required treatment and the investigator withdrew the subject from the trial. the monitor reports to the sponsor and the sponsor notifies the fda and participating investigators. who is responsible for reporting to reviewing irbs?
